newsSandoz to file for approval of aflibercept biosimilar16 August 2023 | By Caroline Peachey (European Pharmaceutical Review)Sandoz intends to seek regulatory approval for its aflibercept biosimilar in the US and EU in the coming months.
newsAstellas and Bayer announce management changes10 February 2023 | By Catherine Eckford (European Pharmaceutical Review)Two Big Pharma companies have announced management changes in 2023: Astellas will have a new President and CEO and Bayer AG will be led by a new CEO.
newsGrünenthal to buy NebidoTM testosterone treatment from Bayer for €500m18 July 2022 | By Caroline Peachey (European Pharmaceutical Review)Privately-owned Grünenthal estimates the Nebido brand will add about €100 million to its EBITDA in 2023.
newsNew Berlin site to accelerate cell therapy innovation for BlueRock Therapeutics14 June 2022 | By Sarah Wills (European Pharmaceutical Review)BlueRock Therapeutics LP has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany.
newsBayer tops out new Leverkusen production facility16 May 2022 | By European Pharmaceutical ReviewThe new €275 million facility will be used to manufacture medicinal products for cancer and cardiovascular diseases and is scheduled to be ready for operation in 2024.
articleNew year, new cell and gene therapy collaborations11 January 2022 | By Hannah Balfour (European Pharmaceutical Review)Here we run down four new research collaborations in the cell and gene therapy sector, announced by Bayer, BMS, Pfizer and Moderna.
newsBayer appoints Head of Research and Early Development for Oncology27 July 2021 | By Anna Begley (European Pharmaceutical Review)Bayer have announced that Professor Dominik Ruettinger will be its new Head of Research and Early Development for Oncology, effective 1 October 2021.
newsBayer to support development and supply of CVnCoV COVID-19 vaccine7 January 2021 | By Hannah Balfour (European Pharmaceutical Review)Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
newsAnti-malarial drugs donated to aid fight against COVID-1924 March 2020 | By Hannah Balfour (European Pharmaceutical Review)The producers of hydroxychloroquine have stated they will donate 130 million doses if the drug is approved as a treatment for the COVID-19 coronavirus.
newsPrimary endpoint met in drug study for worsening chronic heart failure19 November 2019 | By Rachael Harper (European Pharmaceutical Review)A study evaluating the efficacy and safety of vericiguat, a treatment for patients with worsening chronic heart failure, has met the primary efficacy endpoint.
newsDrug makers file complaint for regulations to lower Canadian drug prices27 August 2019 | By Victoria Rees (European Pharmaceutical Review)Five pharma companies have filed a complaint in Canadian court over new rules intended to lower the price of drugs in the country.
newsGlobal cephalosporin drugs market projected to rise 3.34 percent19 August 2019 | By Victoria Rees (European Pharmaceutical Review)The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
newsEMA recommends Vitrakvi for EU marketing authorisation29 July 2019 | By Victoria Rees (European Pharmaceutical Review)The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
newsGlobal diabetes drug market expected to rise 3.6 percent25 June 2019 | By Victoria Rees (European Pharmaceutical Review)A new report predicts that the global diabetes drug market will rise to US$58.4 billion by 2025.
newsNexavar receives final appraisal for primary liver cancer10 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz-300x278.jpg)
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz.jpg)
